All In Biotech

Drug Trial Radar · NCT05804669

A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome

A Phase 1b/2a Open-label Multiple-ascending Dose Exploratory Study of CRN04894 in ACTH-dependent Cushing's Syndrome (Cushing's Disease or Ectopic ACTH Syndrome)

Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

19

Actual

Start

Oct 12, 2023

Primary completion

Aug 25, 2026

Study completion Sep 8, 2026

Sponsor

Lead sponsor
Crinetics Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Apr 7, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 1b/2a, first-in-disease, open-label, multiple-ascending dose exploratory study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamic biomarker responses associated with CRN04894 (an adrenocorticotropic hormone \[ACTH\] receptor antagonist) in participants with ACTH-dependent Cushing's syndrome (Cushing's disease or Ectopic ACTH Syndrome \[EAS\])

Conditions

  • Cushing Syndrome
  • Cushing Disease
  • Ectopic ACTH Syndrome

Interventions

  • atumelnantDrug

    Atumelnant is an orally active investigational agent which antagonizes the action of ACTH at its receptor administered as oral tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants with treatment emergent adverse events (TEAEs)Time frame: Up to Day 15
  2. Proportion of participants with adrenal insufficiencyTime frame: Up to Day 15
  3. Proportion of participants with safety findings determined by laboratory testingTime frame: Up to Day 15
  4. Assessment of the maximum observed plasma concentration of CRN04894Time frame: Up to Day 15
  5. Assessment of the time to achieve maximum observed plasma concentration of CRN04894Time frame: Up to Day 15
  6. Assessment of the plasma area under the curve of CRN04894Time frame: Up to Day 15

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Institutes of Health (NIH) - National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    Bethesda, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.